Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Active, not recruiting · Phase 2 · NCT06632951
Conditions: Urothelial Carcinoma
At a glance
- Research payments reported, 2025
- $588,801
- U.S. investigators named
- 14
- Sites paid
- 12
- Planned or actual enrollment
- 150
About the trial
- Sponsor
- AbbVie
- Tested
- Livmoniplimab (drug), Budigalimab (drug), Docetaxel (drug), Paclitaxel (drug), Docetaxel (drug), Paclitaxel (drug), Gemcitabine (drug)
- Dates
- Started 2025-01-20; completion 2028-08
- Results posted
- Not yet
Urothelial carcinoma (UC) is the ninth most common cancer type worldwide. While the treatment of front-line metastatic urothelial carcinoma (mUC) has improved, there remains a high unmet need for effective therapies for participants who have recurrent disease and disease that has progressed after frontline treatment. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of mUC. There are 3 treatment arms in this study and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at one of 2 …
From ClinicalTrials.gov, last updated 2025-08-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $588,801 in research payments for this study in 2025 (41 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- J T. Beck, M.D., F.A.C.P. Hematology & Oncology · Springdale, AR
- Firas N. Shadad, MD Hematology & Oncology · Goodyear, AZ
- Terence W. Friedlander, MS Hematology & Oncology · San Francisco, CA
- Joseph W. Kim, MD Medical Oncology · New Haven, CT
- Jamal G. Misleh, MD Hematology & Oncology · Newark, DE
- Heather D. Mannuel, MD Medical Oncology · Baltimore, MD
- Eric D. Batts, M.D. Hematology & Oncology · Holland, MI
- Jason Brown, MD Hematology & Oncology · Ann Arbor, MI
- Matthew D. Galsky, MD Medical Oncology · New York, NY
- Yuanquan Yang, M.D. Medical Oncology · Columbus, OH
- Benjamin Garmezy, MD Hematology & Oncology · Nashville, TN
- Michael W. Lattanzi Hematology & Oncology · Austin, TX
- Jue Wang, MD Medical Oncology · Dallas, TX
- Stephan D. Kendall, M.D. Medical Oncology · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Yale University $102,122
- Sarah Cannon Research Institute LLC $90,900
- The University of Texas $57,091
- The Oneoncology Research Network $52,503
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $51,018
- The Ohio State University $49,917
- Icahn School of Med at Mt Sinai $49,035
- Rainbow Babies and Childrens Hospital, OH $40,950
- Iho Corporation $35,777
- Maryland Board of Pharmacy $34,539
- City of Hope National Medical Ctr $22,000
- Highlands Oncology Group PA $2,949
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.